ClinicalTrials.gov record
Active, not recruiting Phase 1Phase 2 Interventional

A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer

ClinicalTrials.gov ID: NCT04194554

Public ClinicalTrials.gov record NCT04194554. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 4, 2026, 6:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center Trial of Androgen Suppression With Abiraterone aCetate, LEuprolide, PARP Inhibition and Stereotactic Body Radiotherapy (ASCLEPIuS): A Phase I/2 Trial in High Risk and Node Positive Prostate Cancer

Study identification

NCT ID
NCT04194554
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Enrollment
102 participants

Conditions and interventions

Interventions

  • Abiraterone Acetate Drug
  • Leuprolide Drug
  • Niraparib Drug
  • Stereotactic body radiotherapy (SBRT) Radiation

Drug · Radiation

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 5, 2020
Primary completion
Apr 30, 2027
Completion
Apr 30, 2029
Last update posted
Apr 30, 2026

2020 – 2029

United States locations

U.S. sites
6
U.S. states
5
U.S. cities
5
Facility City State ZIP Site status
University of Michigan Rogel Cancer Center Ann Arbor Michigan 48109
Mayo Clinic Rochester Minnesota 55901
Cornell University New York New York 10065
Weill Cornell Medicine New York New York 10065
University Hospitals Seidman Cancer Center Cleveland Ohio 44106
University of Texas Southwestern Dallas Texas 75390

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04194554, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 30, 2026 · Synced May 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04194554 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →